AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31097860 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg Ringer's solution (R group)
Number of subjects: 70
Study 31097860 — intervention group
Group type: COMPARATOR
Intervention: 10 ml/kg Voluven (V group)
Number of subjects: 70
Study 31097860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (R group and V group)
Number of subjects: 70
Study 27881555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily plus P2Y12 inhibitor for 12 months (group 1)
Number of subjects: 2124
Study 27881555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily with DAPT stratification (group 2)
Number of subjects: 2124
Study 27881555 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted VKA daily with DAPT stratification (group 3)
Number of subjects: 2124
Study 25905835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandated coverage for colorectal cancer screening
Number of subjects: 0
Study 24188941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg body weight of honey daily for 4 weeks
Number of subjects: 40
Study 24188941 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of loratadine daily for 4 weeks
Number of subjects: 40
Study 24188941 — intervention group
Group type: COMPARATOR
Intervention: Honey-flavored corn syrup as placebo
Number of subjects: 40
Study 21331055 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 17
Study 21331055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19282468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 490
Study 19282468 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m(2)/3 weeks)
Number of subjects: 490
Study 17578320 — intervention group
Group type: EXPERIMENTAL
Intervention: nmAP (1.5 ml on Shenque acupoint once daily, placebo liquid 10 ml twice daily)
Number of subjects: 180
Study 17578320 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste on Shenque acupoint, Shanmai Jianpi Oral Liquid (10 ml twice daily)
Number of subjects: 180
Study 17578320 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste on Shenque acupoint, placebo liquid (10 ml twice daily)
Number of subjects: 180
Study 15100617 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 34
Study 15100617 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg (placebo)
Number of subjects: 34
Study 11605096 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 69
Study 11605096 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-associated stimuli with information that the drink contained caffeine
Number of subjects: 69
Study 11605096 — intervention group
Group type: EXPERIMENTAL
Intervention: Information that the drink contained caffeine
Number of subjects: 69
Study 11605096 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (0 mg/kg)
Number of subjects: 69
Study 9532330 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (15‐20 mg/kg daily divided to 3 equal doses)
Number of subjects: 15
Study 7521784 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release hydromorphone every 12 hours
Number of subjects: 48
Study 7521784 — intervention group
Group type: COMPARATOR
Intervention: Immediate release hydromorphone every 4 hours
Number of subjects: 48
Study 2589661 — intervention group
Group type: EXPERIMENTAL
Intervention: Active airway humidification with MR450 Servo airway heater and humidifier set at 37 degrees C (n = 10)
Number of subjects: 30
Study 2589661 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive airway humidification with Humid‐Vent Mini heat and moisture exchanger (n = 10)
Number of subjects: 30
Study 2589661 — intervention group
Group type: COMPARATOR
Intervention: No airway humidification and heating (control, n = 10)
Number of subjects: 30
Study 1092294 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of deposteroid (methylprednisolone acetate) injected into the base of each tonsillar fossa
Number of subjects: 165
Study 1092294 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected into the base of each tonsillar fossa
Number of subjects: 165
Study 31934980 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 40
Study 31934980 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 40
Study 30445937 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care group (DG)
Number of subjects: 257
Study 30445937 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 257
Study 29262471 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D level in ASD children
Number of subjects: 87
Study 29262471 — intervention group
Group type: COMPARATOR
Intervention: Normal vitamin D levels
Number of subjects: 87
Study 29262471 — intervention group
Group type: COMPARATOR
Intervention: Insufficient vitamin D levels
Number of subjects: 87
Study 29262471 — intervention group
Group type: COMPARATOR
Intervention: Deficient vitamin D levels
Number of subjects: 87
Study 29262471 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D level
Number of subjects: 87
Study 25562462 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone plus counseling
Number of subjects: 360
Study 25125053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac + Acetazolamide (250 mg acetazolamide before anesthetic induction and 30 mg ketorolac in the immediate postoperative period)
Number of subjects: 62
Study 25125053 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (30 mg in the immediate postoperative period)
Number of subjects: 62
Study 19966102 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-associated autologous chondrocyte implantation
Number of subjects: 21
Study 19966102 — intervention group
Group type: EXPERIMENTAL
Intervention: Original periosteal flap technique
Number of subjects: 21
Study 19057629 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Number of subjects: 40
Study 19057629 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural injections with 0.5% lidocaine 9 mL mixed with 1 mL of steroid
Number of subjects: 40
Study 16849364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby in mother's bed with cot-side
Number of subjects: 64
Study 16849364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby in side-car crib attached to mother's bed
Number of subjects: 64
Study 16849364 — intervention group
Group type: COMPARATOR
Intervention: Baby in stand-alone cot adjacent to mother's bed
Number of subjects: 64
Study 12499349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched nutrition
Number of subjects: 29
Study 12499349 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 29
Study 12499349 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched diet in rats
Number of subjects: 29
Study 12499349 — intervention group
Group type: COMPARATOR
Intervention: Control diet in rats
Number of subjects: 29
Study 10744893 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent teacher modeling
Number of subjects: 58
Study 10744893 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthusiastic teacher modeling
Number of subjects: 58
Study 10744893 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthusiastic teacher modeling with competing peer model
Number of subjects: 58
Study 8741094 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg ketoprofen lysine salt
Number of subjects: 60
Study 8741094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2067317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (1200 mg, single oral dosage)
Number of subjects: 48
Study 2067317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 204
Study 6618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (azathioprine and prednisolone)
Number of subjects: 204
Study 6618436 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine therapy
Number of subjects: 204
Study 6618436 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 204
Study 31660654 — intervention group
Group type: EXPERIMENTAL
Intervention: PARK2 mutation (c.155delA)
Number of subjects: 7849
Study 31660654 — intervention group
Group type: EXPERIMENTAL
Intervention: SNCA, LRRK2, KANSL1/MAPT, HLA-DQB1
Number of subjects: 7849
Study 31660654 — intervention group
Group type: COMPARATOR
Intervention: Known loci
Number of subjects: 7849
Study 31660654 — intervention group
Group type: COMPARATOR
Intervention: 28 known genes/loci
Number of subjects: 7849
Study 30110086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc R25/.08 + Clearsonic tip
Number of subjects: 45
Study 30110086 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearsonic tip + Reciproc R25/.08
Number of subjects: 45
Study 30110086 — intervention group
Group type: COMPARATOR
Intervention: Reciproc R25/.08
Number of subjects: 45
Study 28232467 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural writing therapy (IB-CBWT) for PTSD, guided by a therapist, comprising two written assignments per week over a 5-week period.
Number of subjects: 0
Study 28232467 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) control group receiving treatment after a waiting period of 5 weeks.
Number of subjects: 0
Study 28232467 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural writing therapy (IB-CBWT) for PTSD.
Number of subjects: 0
Study 25604313 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (intensive)
Number of subjects: 96
Study 25604313 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (conventional)
Number of subjects: 96
Study 23086679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutanplast
Number of subjects: 100
Study 23086679 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 100
Study 21044517 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching-Learning contexts
Number of subjects: 2020
Study 21044517 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal model of academic performance
Number of subjects: 2020
Study 18173612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 7%-tetracaine 7% peel applied for 30, 60, or 90 min over a 50-, 100-, or 200-cm² area
Number of subjects: 36
Study 18173612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 7%-tetracaine 7% peel
Number of subjects: 36
Study 16314879 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (CHO) drinks (2.1 MJ/day)
Number of subjects: 12
Study 16314879 — intervention group
Group type: COMPARATOR
Intervention: High-fat (FAT) drinks (2.1 MJ/day)
Number of subjects: 12
Study 16314879 — intervention group
Group type: COMPARATOR
Intervention: High-protein (PRO) drinks (2.1 MJ/day)
Number of subjects: 12
Study 14676650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (intracranial temperature, 34 degrees C) for 48 hours followed by rewarming at a rate of 1 degrees C per day for 3 days
Number of subjects: 17
Study 14676650 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (intracranial temperature, 37 degrees C) for 5 days
Number of subjects: 17
Study 11967819 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study 11967819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 8991338 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nurses using the ACCS and MAFS for pain ratings
Number of subjects: 124
Study 8991338 — intervention group
Group type: COMPARATOR
Intervention: Control nurses using customary method of assessment
Number of subjects: 124
Study 8431125 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium:YAG laser dissection at 15 W continuous beam
Number of subjects: 100
Study 8431125 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgical dissection with 'L' hook and spatula electrodes at 25 W coagulation current
Number of subjects: 100
Study 3429696 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 60 mg (LA 60 mg)
Number of subjects: 34
Study 3429696 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol 20 mg tid
Number of subjects: 34
Study 30322091 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf powder (20 g)
Number of subjects: 27
Study 30322091 — intervention group
Group type: COMPARATOR
Intervention: Control meal (CNT)
Number of subjects: 27
Study 27371106 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting telephone follow-up intervention
Number of subjects: 91
Study 27371106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 23452836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal injection(s) of autologous adherent bone marrow cells combined with physical therapy
Number of subjects: 70
Study 23452836 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 70
Study 24509458 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided transanal hemorrhoid dearterialization with mucopexy
Number of subjects: 50
Study 24509458 — intervention group
Group type: COMPARATOR
Intervention: Hemorrhoidectomy
Number of subjects: 50
Study 22303910 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg
Number of subjects: 0
Study 22303910 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/5 mg
Number of subjects: 0
Study 22303910 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren 300 mg
Number of subjects: 0
Study 22303910 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine SPCs (both dosages combined)
Number of subjects: 0
Study 21195988 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 66
Study 21195988 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 66
Study 17184371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 0
Study 17184371 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding programmes (prompted voiding, habit retraining, timed voiding)
Number of subjects: 0
Study 17184371 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 16123483 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant group (G-CSF-mobilized PBMNCs)
Number of subjects: 28
Study 16123483 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 11879208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 MAC sevoflurane with remifentanil
Number of subjects: 3
Study 11879208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 MAC sevoflurane with remifentanil
Number of subjects: 3
Study 11879208 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 microg x kg(‐1) x h(‐1) remifentanil and 1.24% end‐tidal sevoflurane
Number of subjects: 3
Study 10630837 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamines and amphetamine derivatives (mazindol, dextroamphetamine, methylphenidate)
Number of subjects: 0
Study 10630837 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8866625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised fenoterol (2 mg)
Number of subjects: 13
Study 8866625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (2 mg)
Number of subjects: 13
Study 8866625 — intervention group
Group type: COMPARATOR
Intervention: Saline control (0.45% saline)
Number of subjects: 13
Study 8866625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol and salbutamol
Number of subjects: 13
Study 1610589 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day preoperative treatment with oral administration of 60 mg diltiazem 3 times daily, 10 mg diltiazem intravenously as a bolus dose before the beginning of the cardiopulmonary bypass, and 5 mg diltiazem intravenously 10 min before removal of aortic clamp
Number of subjects: 90
Study 1610589 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day preoperative treatment with oral administration of 60 mg diltiazem 3 times daily
Number of subjects: 90
Study 1610589 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diltiazem intravenously as a bolus dose before the beginning of CPB and 5 mg 10 min before removal of the aortic clamp
Number of subjects: 90
Study 1610589 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diltiazem in 1000 ml cardioplegic solution, given as additive
Number of subjects: 90
Study 1610589 — intervention group
Group type: COMPARATOR
Intervention: Control group not receiving diltiazem
Number of subjects: 90
Study 6142775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 11
Study 6142775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31640613 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Ratio version of the CBM program (Arm 1)
Number of subjects: 498
Study 31640613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ratio 'active' CBM program (Arm 2)
Number of subjects: 498
Study 31640613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ratio CBM program with adherence promotion (Arm 3)
Number of subjects: 498
Study 31640613 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 498
Study 29754673 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 2331
Study 29754673 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2331
Study 27401339 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's procedure
Number of subjects: 0
Study 27401339 — intervention group
Group type: COMPARATOR
Intervention: Intersphincteric abdominoperineal excision
Number of subjects: 0
Study 27401339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 25269598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g every 24 hours intravenously for 4 days in addition to standard stroke-unit care
Number of subjects: 0
Study 25269598 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke-unit care without preventive antibiotic therapy
Number of subjects: 0
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyman-Kutcher-Burman (LKB) model
Number of subjects: 512
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Seriality (RS) model
Number of subjects: 512
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic model
Number of subjects: 512
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: LKB model
Number of subjects: 512
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline toxicity score
Number of subjects: 512
Study 21664059 — intervention group
Group type: EXPERIMENTAL
Intervention: All models
Number of subjects: 512
Study 20124169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (79.2 GyE)
Number of subjects: 393
Study 20124169 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose radiation therapy (70.2 GyE)
Number of subjects: 393
Study 17353238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg loading dose/50 mg every 12 h
Number of subjects: 35
Study 17353238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 50 mg loading dose/25 mg every 12 h
Number of subjects: 35
Study 17353238 — intervention group
Group type: COMPARATOR
Intervention: All pathogens combined
Number of subjects: 35
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive sodium intake
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low potassium intake
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake of fish oil
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium intake
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnesium intake
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive coffee consumption
Number of subjects: 0
Study 16302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive alcohol intake
Number of subjects: 0
Study 11886356 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP 2 g/day
Number of subjects: 24
Study 11886356 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP 1 g/day
Number of subjects: 24
Study 9817153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air exposure (‐23 degrees C)
Number of subjects: 8
Study 9817153 — intervention group
Group type: COMPARATOR
Intervention: Normal indoor air exposure (+22 degrees C)
Number of subjects: 8
Study 7843440 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal levonorgestrel‐releasing implant
Number of subjects: 19
Study 7843440 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine device (IUD) releasing levonorgestrel
Number of subjects: 19
Study 7843440 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 1334803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prinivil 10 to 40 mg once daily
Number of subjects: 135
Study 1334803 — intervention group
Group type: COMPARATOR
Intervention: Procardia XL 30 to 120 mg once daily
Number of subjects: 135
Study 6502311 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine superoxide dismutase (0.25 mg/kg)
Number of subjects: 45
Study 6502311 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 45
Study 30859515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline screening for diabetes and prediabetes
Number of subjects: 196
Study 29935150 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (intervention group)
Number of subjects: 4
Study 27113085 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 452